インプラントでCAR-T細胞を作り出し、がんに効くことを動物実験で確認(In Animal Study, Implant Churns Out CAR-T Cells to Combat Cancer)

ad

2022-03-24 ノースカロライナ州立大学

・ノースカロライナ州立大学とノースカロライナ大学チャペルヒル校の研究者は、がん腫瘍を攻撃するCAR-T細胞を生成・放出する埋め込み型のバイオテクノロジーを開発した。
・マウスのリンパ腫を対象とした概念実証試験において、このインプラントによる治療が、従来のCAR-T細胞によるがん治療よりも迅速かつ効果的であることを確認したとのこと。

<関連情報>

CAR-T細胞を生体内で迅速に製造・放出するための生体再建型移植用スキャフォールド Bioinstructive implantable scaffolds for rapid in vivo manufacture and release of CAR-T cells

Pritha Agarwalla,Edikan A. Ogunnaike,Sarah Ahn,Kristen A. Froehlich,Anton Jansson,Frances S. Ligler,
Gianpietro Dotti &Yevgeny Brudno
Published: 24 March 2022

インプラントでCAR-T細胞を作り出し、がんに効くことを動物実験で確認(In Animal Study, Implant Churns Out CAR-T Cells to Combat Cancer)

Abstract

Despite their clinical success, chimeric antigen receptor (CAR)-T cell therapies for B cell malignancies are limited by lengthy, costly and labor-intensive ex vivo manufacturing procedures that might lead to cell products with heterogeneous composition. Here we describe an implantable Multifunctional Alginate Scaffold for T Cell Engineering and Release (MASTER) that streamlines in vivo CAR-T cell manufacturing and reduces processing time to a single day. When seeded with human peripheral blood mononuclear cells and CD19-encoding retroviral particles, MASTER provides the appropriate interface for viral vector-mediated gene transfer and, after subcutaneous implantation, mediates the release of functional CAR-T cells in mice. We further demonstrate that in vivo-generated CAR-T cells enter the bloodstream and control distal tumor growth in a mouse xenograft model of lymphoma, showing greater persistence than conventional CAR-T cells. MASTER promises to transform CAR-T cell therapy by fast-tracking manufacture and potentially reducing the complexity and resources needed for provision of this type of therapy.

医療・健康
ad
ad
Follow
ad
タイトルとURLをコピーしました